Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013347712> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2013347712 endingPage "262" @default.
- W2013347712 startingPage "254" @default.
- W2013347712 abstract "Safety pharmacological studies need to be performed according to ICH S7A Guidelines for finished formulations that substantially alter the pharmacokinetics and/or pharmacodynamics of the active substance in comparison to formulations previously tested (i. e. through active excipients such as penetration enhancers, liposomes, and other changes such as polymorphous system). In the present study, amorphous formulation of celecoxib (CAS 169590-42-5), a new patented formulation with altered pharmacokinetic profile was investigated in comparison with the standard crystalline celecoxib (CEL) for its undesirable pharmacodynamic effects using certain safety pharmacological studies. The effects of the new formulation on vital functions using safety pharmacology core battery like central nervous system (CNS) (functional observation battery, locomotor activity, and motor coordination) and cardiovascular system (CVS) (blood pressure, heart rate and QT interval) were investigated in laboratory rodents. In addition, supplementary safety pharmacology study on gastrointestinal system (GIT) (gastric injury potential, gastric secretion) was also carried out. Oral administration of a single dose of the amorphous celecoxib formulation (CF) varying of 50, 150 and 500 mg/kg was studied in comparison with vehicle treated control and crystalline celecoxib in animals. The maximum tolerated dose (MTD) was identified by administration of insufferable doses of amorphous formulation, extended up to 2 000 mg/kg during the experiments on physiological parameters. There were no CNS and GIT safety concerns raised with respect to use of CF except the arrythmogenic risk associated with QT interval prolongation upon the high dose of CF." @default.
- W2013347712 created "2016-06-24" @default.
- W2013347712 creator A5034155105 @default.
- W2013347712 creator A5039538410 @default.
- W2013347712 creator A5040694487 @default.
- W2013347712 creator A5083542664 @default.
- W2013347712 creator A5087544485 @default.
- W2013347712 date "2011-12-13" @default.
- W2013347712 modified "2023-09-25" @default.
- W2013347712 title "Preclinical Safety Pharmacological Studies on the Amorphous Formulation of Celecoxib" @default.
- W2013347712 doi "https://doi.org/10.1055/s-0031-1296394" @default.
- W2013347712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19537527" @default.
- W2013347712 hasPublicationYear "2011" @default.
- W2013347712 type Work @default.
- W2013347712 sameAs 2013347712 @default.
- W2013347712 citedByCount "2" @default.
- W2013347712 countsByYear W20133477122013 @default.
- W2013347712 crossrefType "journal-article" @default.
- W2013347712 hasAuthorship W2013347712A5034155105 @default.
- W2013347712 hasAuthorship W2013347712A5039538410 @default.
- W2013347712 hasAuthorship W2013347712A5040694487 @default.
- W2013347712 hasAuthorship W2013347712A5083542664 @default.
- W2013347712 hasAuthorship W2013347712A5087544485 @default.
- W2013347712 hasConcept C111113717 @default.
- W2013347712 hasConcept C112705442 @default.
- W2013347712 hasConcept C118441451 @default.
- W2013347712 hasConcept C2776190711 @default.
- W2013347712 hasConcept C2776467144 @default.
- W2013347712 hasConcept C2780035454 @default.
- W2013347712 hasConcept C42219234 @default.
- W2013347712 hasConcept C71924100 @default.
- W2013347712 hasConcept C98274493 @default.
- W2013347712 hasConceptScore W2013347712C111113717 @default.
- W2013347712 hasConceptScore W2013347712C112705442 @default.
- W2013347712 hasConceptScore W2013347712C118441451 @default.
- W2013347712 hasConceptScore W2013347712C2776190711 @default.
- W2013347712 hasConceptScore W2013347712C2776467144 @default.
- W2013347712 hasConceptScore W2013347712C2780035454 @default.
- W2013347712 hasConceptScore W2013347712C42219234 @default.
- W2013347712 hasConceptScore W2013347712C71924100 @default.
- W2013347712 hasConceptScore W2013347712C98274493 @default.
- W2013347712 hasIssue "05" @default.
- W2013347712 hasLocation W20133477121 @default.
- W2013347712 hasLocation W20133477122 @default.
- W2013347712 hasOpenAccess W2013347712 @default.
- W2013347712 hasPrimaryLocation W20133477121 @default.
- W2013347712 hasRelatedWork W1758514097 @default.
- W2013347712 hasRelatedWork W1997101420 @default.
- W2013347712 hasRelatedWork W2010116591 @default.
- W2013347712 hasRelatedWork W2013347712 @default.
- W2013347712 hasRelatedWork W2227061539 @default.
- W2013347712 hasRelatedWork W2546247047 @default.
- W2013347712 hasRelatedWork W2594910449 @default.
- W2013347712 hasRelatedWork W2766361185 @default.
- W2013347712 hasRelatedWork W2992709639 @default.
- W2013347712 hasRelatedWork W3135583773 @default.
- W2013347712 hasVolume "59" @default.
- W2013347712 isParatext "false" @default.
- W2013347712 isRetracted "false" @default.
- W2013347712 magId "2013347712" @default.
- W2013347712 workType "article" @default.